Matthew L Sherman
CIK 1325710 · EVP & Chief Medical Officer · last filed 2024-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$168
Companies
5
Total Filings
77
Lifetime Open-Market Net
-$7.83M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | EVP & Chief Medical Officer | 0 | $25.59 | $0 | -$445.2K | 21 | 2024-06-11 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | — | $13.60 | — | $0 | 7 | 2023-06-23 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | — | — | — | $0 | 3 | 2019-08-02 |
| PULM | Director | 100 | $1.68 | $168 | $0 | 5 | 2019-05-20 |
| ACCELERON PHARMA INC (XLRN) Delisted | EVP & Chief Medical Officer | 77,267 | $178.75 | $13.81M | -$7.39M | 41 | 2018-04-04 |
Recent Filings · Page 3 of 8
77 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-18 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Exer (M) | +2,697 | $92.9K | EDGAR |
| 2020-10-06 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Tax (F) | −2,632 | -$134.6K | EDGAR |
| 2020-06-25 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | +1,760 | $0 | EDGAR |
| 2020-01-28 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-17 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2019-08-02 | LUMOS PHARMA, INC. (NLNK) Delisted | Mixed | — | $0 | EDGAR |
| 2019-05-20 | PULM | Grant (A) | — | $0 | EDGAR |
| 2019-05-14 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-29 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.